Remove Diabetes Remove Heart attacks Remove Strokes
article thumbnail

Research shows sotagliflozin is the first medication of its kind to significantly reduce both heart attacks and strokes

Medical Xpress - Cardiology

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart attack and stroke among these patients, according to results from an international clinical trial led by a Mount Sinai researcher.

article thumbnail

Clear shift in arterial diseases in diabetes

Science Daily - Heart Disease

There has been a redistribution in the risk of arterial disease in type 1 and 2 diabetes. The risks of heart attack and stroke have decreased significantly, while complications in more peripheral vessels have increased in relative importance, according to new studies.

Diabetes 122
article thumbnail

SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney Disease

Med Page Today

(MedPage Today) -- The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk patients with type 2 diabetes (T2D), chronic kidney disease (CKD), and cardiovascular risk factors, a prespecified.

article thumbnail

A diabetes, heart failure, and kidney disease medication is the first of its kind to significantly reduce both heart attacks and strokes

Science Daily - Heart Disease

New research shows sotagliflozin is the only drug in its class to demonstrate these results.

article thumbnail

Researchers report clear shift in arterial diseases in diabetes

Medical Xpress - Cardiology

There has been a redistribution in the risk of arterial disease in type 1 and 2 diabetes. The risks of heart attack and stroke have decreased significantly, while complications in more peripheral vessels have increased in relative importance, according to studies at the University of Gothenburg.

article thumbnail

Sotagliflozin Cuts MACE Risk By 23% in Patients with Type 2 Diabetes, CKD

HCPLive

Dual SGLT1/2 inhibition with sotagliflozin significantly reduced both heart attacks and stroke in a prespecified secondary analysis of the SCORED trial.

article thumbnail

Chelation Flops for Cardio Health After Heart Attack

Med Page Today

(MedPage Today) -- ATLANTA -- Chelation to remove lead and other heavy metals didn't improve outcomes for type 2 diabetes patients after myocardial infarction (MI), the TACT2 trial showed. Cumulative incidence of time to first event (MI, stroke.